
July 9 (Reuters) - Merck MRK.N will buy UK-based Verona Pharma VRNA.O for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of its blockbuster cancer drug.